Literature DB >> 468886

[Fluorometric determination of "activated" cyclophosphamide and ifosfamide in blood (author's transl)].

G Voelcker, R Haeglsperger, H J Hohorst.   

Abstract

"Activated" N-(2-Chloroethyl)amido-oxazaphosphorines like 4-hydroxycyclophosphamide, 4-hydroperoxycyclophosphamide, 4-hydroxyifosfamide, and 4-hydroperoxyifosfamide can be determined fluorometrically by condensation of liberated acrolein with m-aminophenol yielding 7-hydroxychinolin. The method permits determination of 10(-10) mol and is specific for "activated" N-(2-Chloroethyl)amido-oxazaphosphorine metabolites which liberate acrolein under conditions of the test. Neither cyclophosphamide nor ifosfamide or other metabolites of this cytostatics interfere with the test. Blood levels of free 4-hydroxycyclophosphamide and 4-hydroxyifosfamide were determined after injection of cyclophosphamide and ifosfamide into mice.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 468886     DOI: 10.1007/bf00964578

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  11 in total

1.  [ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].

Authors:  N BROCK; H J HOHORST
Journal:  Arzneimittelforschung       Date:  1963-12

2.  Synthesis of 4-hydroperoxy derivatives of ifosfamide and trofosfamide by direct ozonation and preliminary antitumor evaluation in vivo.

Authors:  H J Hohorst; G Peter; R F Struck
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

3.  Synthesis and metabolic behavior of the suggested active species of isophosphamide having cytostatic activity.

Authors:  A Takamizawa; S Matsumoto; T Iwata; Y Tochino; K Katagiri
Journal:  J Med Chem       Date:  1974-11       Impact factor: 7.446

4.  4-Ketocyclophosphamide, a metabolite of cyclophosphamide. Formation, chemical and biological properties.

Authors:  H J Hohorst; A Ziemann; N Brock
Journal:  Arzneimittelforschung       Date:  1971-08

5.  Fluorometric determination of acrolein and related compounds with m-aminophenol.

Authors:  R A Alarcon
Journal:  Anal Chem       Date:  1968-09       Impact factor: 6.986

6.  [Isolation and characterisation of two main metabolites of ifosfamide from human urine (author's transl)].

Authors:  K Norpoth; G Müller; H Raidt
Journal:  Arzneimittelforschung       Date:  1976

7.  Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative.

Authors:  M Przybylski; H Ringsdorf; U Lenssen; G Peter; G Voelcker; T Wagner; H J Hohorst
Journal:  Biomed Mass Spectrom       Date:  1977-08

8.  Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.

Authors:  G Peter; T Wagner; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

9.  The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.

Authors:  H J Hohorst; U Draeger; G Peter; G Voelcker
Journal:  Cancer Treat Rep       Date:  1976-04

10.  [Studies on the spontaneous decomposition of 4-hydroxyphosphamide and 4-hydroperoxyphosphamide by means of thin-layer chromatography].

Authors:  G Völker; U Dräger; G Peter; H J Hohorst
Journal:  Arzneimittelforschung       Date:  1974-08
View more
  7 in total

1.  Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites.

Authors:  U Schuler; G Ehninger; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Experimental toxicology of ASTA Z 7557 (INN mafosfamide).

Authors:  J Pohl; P Hilgard; W Jahn; H J Zechel
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.

Authors:  T Wagner; D Heydrich; T Jork; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

4.  Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study.

Authors:  R N Harris; P J Basseches; P L Appel; A M Durski; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane.

Authors:  S Rosenow; K L Kooistra; G Powis; R A Van Dyke
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.

Authors:  G Peter; H J Hohorst
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 7.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.